A Surprising Match
Imagine sitting quietly when you suddenly feel your heart skip a beat or flutter in your chest. For millions of people, these sensations—called premature atrial contractions (PACs)—are a daily worry. They are often harmless, but frequent flutters can be unsettling and may lead to more serious heart issues.
Now, a new study suggests a surprising solution: a drug originally designed to treat brain conditions may help calm these heart flutters.
PACs are extra, early heartbeats that start in the heart's upper chambers. They are very common. Many people have them and never know. But for others, they cause noticeable symptoms like dizziness, fatigue, or a pounding feeling in the chest.
When PACs happen often, they can be more than just a nuisance. Research shows that frequent PACs are linked to a higher risk of developing atrial fibrillation (a chaotic heart rhythm), stroke, and even heart failure.
Right now, there are no approved medications specifically designed to stop PACs. Doctors often treat the symptoms or the conditions that follow, but not the flutters themselves. This leaves many patients without a direct way to manage their symptoms.
A New Approach to an Old Problem
For years, doctors have focused on the heart’s electrical system—like its built-in wiring—to understand rhythm problems. But this study looks at a different system entirely.
Think of the heart as a house. The electrical system is the wiring that controls the lights. But what if there’s also a chemical messenger system, like a smart home app, that can adjust the settings?
This study focuses on a chemical messenger called glutamate. Glutamate is well-known in the brain for helping nerve cells communicate. But recent research found that the heart has its own glutamate system, too.
Here’s the twist: a drug called memantine, which is already used to treat symptoms of moderate to severe Alzheimer’s disease, works by blocking a specific part of this glutamate system in the brain. The researchers wondered if it could do the same in the heart.
How It Works: A Simple Analogy
Imagine a lock on a door. Glutamate is the key that fits into the lock (a receptor called NMDA) and opens the door, allowing electrical signals to flow. In the heart, too much of this activity might make it easier for flutters and irregular rhythms to start.
Memantine acts like a piece of gum stuck in the lock. It doesn’t break the lock, but it makes it harder for the key to turn. By gently blocking these receptors, memantine may calm the heart’s electrical activity and prevent those extra, early beats from happening.
The Study Snapshot
Researchers conducted a phase 2 clinical trial involving 241 adults with frequent, symptomatic PACs (at least 1,000 per day). The trial was double-blind and placebo-controlled, meaning neither the patients nor the doctors knew who received the real drug or a dummy pill.
Participants were randomly assigned to take either memantine or a placebo for six weeks. The main goal was to see how much the number of heart flutters changed from the start to the end of the study.
The results were clear. People taking memantine saw a much bigger drop in their heart flutters compared to those taking the placebo.
On average, the group taking memantine had a 47% greater reduction in PACs than the placebo group. This difference was statistically significant, meaning it’s unlikely to be due to chance.
The study also looked at "responders"—people whose PAC count dropped by at least half. Over half of the memantine group (52%) met this goal, compared to less than a quarter of the placebo group (23%).
But the benefits didn’t stop there.
Memantine also reduced the burden of nonsustained atrial tachycardia (brief, fast heart rhythms in the upper chambers). And most importantly, fewer people in the memantine group developed new-onset atrial fibrillation (4.8%) compared to the placebo group (23.9%).
But there’s a catch.
This study provides the first clinical proof that targeting the heart’s glutamate system can work in humans. It opens the door to a completely new class of heart rhythm medications—one that doesn’t focus on the heart’s traditional electrical pathways.
While the results are exciting, experts caution that this is just one study. It’s a strong signal, but more research is needed to confirm these findings and understand the long-term effects.
If you experience frequent heart flutters, this research offers hope for a new treatment option in the future. However, memantine is not yet approved for this use.
This does not mean you should start taking memantine for heart flutters.
Always talk to your doctor before starting or stopping any medication. They can help you understand your symptoms and find the best treatment plan for you.
This study was relatively small and lasted only six weeks. It also focused on a specific group of patients with frequent, symptomatic PACs. The results may not apply to everyone with heart flutters.
Additionally, the study was funded by the manufacturer of memantine, which could introduce bias, though the trial design was rigorous.
The next step is to conduct larger, longer-term trials to confirm these findings. If successful, memantine could be studied for approval specifically for treating frequent PACs.
Research like this takes time, but it represents a promising new direction for managing heart rhythm problems. For now, it’s a reminder that sometimes, solutions can come from unexpected places.
